CIDEX ACTIVATED DIALDEHYDE SOLUTION

{0}------------------------------------------------ Special 510(k) Advanced Sterilization Products CIDEX® Activated Dialdehyde Solution #### J. 510(k) Summarv APR 1 2 2006 # Applicant's Name, Address, Telephone, FAX, Contact Information Advanced Sterilization Products A Johnson & Johnson Company Division of Ethicon, Inc. 33 Technology Dr. Irvine, CA 92618 #### Contact Person: Joseph M. Ascenzi, Ph.D., RAC Sr. Manager, Regulatory Affairs Phone: (949) 453-6352 (949) 789-3900 FAX: Email: jascenzi@aspus.jnj.com #### Submission Date March 7, 2006 # Trade Name CIDEX® Activated Dialdehyde Solution # Common Name Liquid Chemical Sterilant # Classification Class II # Legally Marketed Equivalent Device CIDEX® Activated Dialdehyde Solution, K924434 ### Description of Device CIDEX Solution is a liquid chemical sterilant/high level disinfectant used for sterilization/high-level disinfection of heat sensitive semi-critical medical devices that cannot be processed by another process. The active ingredient {1}------------------------------------------------ Page 2 of 3 # Indications for Use CIDEX® Activated Dialdehyde Solution is a liquid chemical sterilant and a high level disinfectant for reprocessing heat sensitive medical/dental devices such as endoscopes, respiratory therapy equipment and ultrasonic transducers. #### Sterilant: CIDEX Solution is a sterilant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by the CIDEX® Solution Test Strip, at 25°C (77°) with an immersion time of at least 10 hours with a reuse period not to exceed 14 days. #### High Level Disinfectant: CIDEX Solution is a high level disinfectant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by the CIDEX® Solution Test Strip, at 25°C (77°) with an immersion time of at least 45 minutes with a reuse period not to exceed 14 days. CIDEX Solution is intended for use in manual systems as well as in automated endoscope reprocessors. ### Description of Modification The modification to the device incorporates an anti-oxidant and solubilizing agent to increase the shelf life of the product beyond the current 2 years. ## Summary of Non-clinical Tests Microbiological activity of the Modified Device was evaluated using the required standard test methods. The sterilization claim and high level disinfection claim for the Modified Device was confirmed to be the same as the Predicate Device. Simulated use studies were conducted to validate the sterilization and high-level disinfection claim. The external surface and internal lumens of three types of endoscopes were inoculated with >10° cfu Bacillus subtilis spores and subjected to 10 hours soaking at 25℃. Sampling of the surface and lumens indicated a >106 log reduction in viable spores. High-level disinfection was verified in a simulated use study using the same three types of scopes whose surfaces and internal lumens were inoculated with >106 cfu Mycobacterium terrae. Exposure to the Modified Device for 45 min at 25℃ reduced the viable M. terrae by >610g10. Stability studies of the Modified Device are in progress. Accelerated stability studies (40°C/75%RH) indicate that the product is stable for 6 months, and increase over the stability of the Predicate Device. Real time stability {2}------------------------------------------------ (30°C/60%RH) is on going. Data at 18 months indicates the product is stable. Data will be collected out to 3 years. # Substantial Equivalence Based on the data obtained from the studies described above, the Modified Device, CIDEX Activated Dialdehyde Solution is substantially equivalent to the Predicate Device. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle faces right and is positioned to the right of the department's name, which is arranged in a circular pattern around the left side of the logo. The text reads "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA". Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 APR 1 2 2006 Dr. Joseph M. Ascenzi Senior Manager, Regulatory Affairs Advanced Sterilization Products Johnson & Johnson Company Division of Ethicon, Incorporated 33 Technology Drive Irvine, California 92618 Re: K060618 Trade/Device Name: CIDEX® Activated Dialdehyde Solution Regulation Number: 880.6885 Regulation Name: Liquid Chemical Sterilants/High Level Disinfectants Regulatory Class: II Product Code: MED Dated: March 28, 2006 Received: March 29, 2006 Dear Dr. Ascenzi: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition. FDA may publish further announcements concerning vour device in the Federal Register. {4}------------------------------------------------ Page 2 - Dr. Ascenzi Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801). please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Sujite Y. Mchia M.D. Chiu Lin. Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ Device Name: CIDEX® Activated Dialdehyde Solution #### Indications for Use: CIDEX® Activated Dialdehyde Solution is a liquid chemical sterilant and a high level disinfectant for reprocessing heat sensitive medical/dental devices such as endoscopes, respiratory therapy equipment and ultrasonic transducers. Sterilant: CIDEX Solution is a sterilant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by the CIDEX® Solution Test Strip, at 25℃ (77°) with an immersion time of at least 10 hours with a reuse period not to exceed 14 days. High Level Disinfectant: CIDEX Solution is a high level disinfectant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by the CIDEX® Solution Test Strip, at 25℃ (77°) with an immersion time of at least 45 minutes with a reuse period not to exceed 14 days. CIDEX Solution is intended for use in manual systems as well as in automated endoscope reprocessors. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-the-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) 4/12/06 any, General Hospi K0406 18 Apr